Related Experiment Video
Updated: Jun 29, 2025
Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers
Published on: February 20, 2017
Genetic determinants of taxane-induced peripheral neuropathy
Abstract:
The efficacy of taxane‑containing regimens has been demonstrated for various cancers, particularly ovarian, endometrial, breast, lung, and prostate cancers. However, extensive taxane-induced toxicities limit their use. Prediction and management of many toxic complications in cancer patients have evolved significantly over the last decade. Peripheral neuropathy is the most typical non-hematological taxane-related complication, and it has a multifactorial pathogenesis. It is often dose-dependent and progressive during therapy and sometimes even after treatment. Unfortunately, the prediction of these common adverse events remains unclear. In the past few years, several polymorphisms of candidate genes with a possible role in the development of this consequence were studied. This minireview aims to highlight the critical yet underappreciated roles of genetic predictors that may increase susceptibility to taxane-induced peripheral neuropathy in cancer patients (Ref. 40). Keywords: taxanes, paclitaxel, docetaxel, peripheral neuropathy, risk factors, genetic polymorphisms.
Insights
Genetic factors may predict taxane-induced peripheral neuropathy (TIPN) risk in cancer patients. Understanding these genetic predictors is crucial for managing this common taxane toxicity.
Area of Science:
- Oncology
- Pharmacogenomics
- Neuroscience
Background:
- Taxane-containing chemotherapy is effective for various cancers but causes significant toxicities.
- Taxane-induced peripheral neuropathy (TIPN) is a common, dose-dependent, and progressive adverse event.
- Predicting and managing TIPN remains challenging despite advances in cancer care.
Purpose of the Study:
- To review the role of genetic predictors in taxane-induced peripheral neuropathy susceptibility.
- To highlight underappreciated genetic factors influencing TIPN risk in cancer patients.
Main Methods:
- Literature review of studies investigating gene polymorphisms and TIPN.
- Analysis of candidate gene polymorphisms associated with taxane toxicity.
Main Results:
- Several gene polymorphisms have been studied for their potential role in TIPN development.
- Genetic variations may influence an individual's susceptibility to developing TIPN.
Conclusions:
- Genetic predictors offer a potential avenue for identifying patients at higher risk of TIPN.
- Further research into genetic factors is essential for personalized taxane therapy and improved patient outcomes.
Related Concept Videos
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
01:15Drugs that Stabilize Microtubules
01:25Mutagenicity and Carcinogenicity